Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the target of a significant increase in short interest in July. As of July 15th, there was short interest totalling 9,000 shares, an increase of 1,185.7% from the June 30th total of 700 shares. Based on an average daily trading volume, of 58,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Galmed Pharmaceuticals in a report on Sunday, July 21st. They issued a “sell” rating on the stock.

Galmed Pharmaceuticals Stock Up 5.0 %

Galmed Pharmaceuticals stock opened at $0.31 on Friday. The stock has a 50-day simple moving average of $0.33 and a 200 day simple moving average of $0.36. Galmed Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $1.26.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its earnings results on Thursday, May 30th. The biopharmaceutical company reported ($0.23) EPS for the quarter.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.